Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to advance the development of PredicineCARE, a blood cfDNA NGS assay, to identify NSCLC patients who may benefit from targeted therapy, APL-101 (vebreltinib), a novel, potent, selective and orally bioavailable small molecule c-Met inhibitor.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: APL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apollomics Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 05, 2024